Region-dependent regulatioin of Tau phosphorylation in a mouse model of tauopathy
This study demonstrates that the cell-surface enzyme GDE2 regulates region-specific Tau phosphorylation and aggregation in a tauopathy mouse model by modulating local kinase activities, thereby identifying GDE2 as a key component of the regulatory network controlling Tau pathology.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
In the human brain, a protein called Tau acts as a vital support beam for the cell's internal transport system. It binds to microscopic tracks known as microtubules, holding them together so that nutrients and signals can travel smoothly along the length of a neuron. Under normal conditions, this protein is carefully managed by a chemical process called phosphorylation, where tiny phosphate groups are attached to or removed from the protein to regulate its function. However, in diseases like Alzheimer's, this balance breaks down. The protein becomes overloaded with these phosphate groups, a state known as hyperphosphorylation. This excess causes the protein to lose its grip on the transport tracks and clump together into tangled masses that damage and eventually kill brain cells. Scientists have long sought to understand exactly what triggers this dangerous shift, hoping that identifying the switch could lead to ways to stop the disease before it causes irreversible harm.
Researchers at Johns Hopkins School of Medicine have now uncovered a new piece of this puzzle, focusing on an enzyme called GDE2. This molecule sits on the surface of nerve cells and acts like a pair of molecular scissors, cutting the anchors that hold certain other proteins to the cell membrane. While previous studies suggested that GDE2 might be involved in Alzheimer's, those earlier findings were complicated by the presence of another major disease factor, amyloid plaques. To see if GDE2 plays a role in Tau problems on its own, the team turned to a specific mouse model that develops Tau tangles without any amyloid buildup. They created a version of these mice that lacked the gene for GDE2 entirely and watched how their brains changed over time, comparing them to normal mice with the same Tau mutation.
The results revealed that GDE2 does not simply turn Tau phosphorylation on or off; instead, it acts as a region-specific regulator that changes the timing of the disease. In the outer layer of the brain, known as the cortex, removing GDE2 had a protective effect. In mice without this enzyme, the harmful phosphorylation of Tau at specific sites that encourage clumping was delayed. While the normal mice showed a sharp rise in these damaging changes by six months of age, the mice without GDE2 did not see this increase until nine months. Furthermore, at the six-month mark, the mice lacking GDE2 had significantly lower levels of these harmful Tau modifications in their cortex. Interestingly, the same removal of GDE2 also accelerated a different type of phosphorylation at a site that actually helps prevent clumping, suggesting the enzyme normally works to keep the protein in a more aggregation-prone state in this part of the brain.
The story was different in the hippocampus, the brain region critical for memory. Here, the absence of GDE2 also delayed the rise of harmful Tau changes at one specific site, but it did not produce the same broad reduction in damage seen in the cortex. Instead, the mice without GDE2 showed a temporary spike in the protective form of phosphorylation at six months. This indicates that the enzyme's influence is not uniform across the brain; it interacts with local chemical environments differently depending on the location. The researchers found that these changes were driven by shifts in the activity of specific enzymes that add phosphate groups, known as kinases. In the cortex, the absence of GDE2 reduced the activity of two key kinases, while in the hippocampus, it increased the activity of one. The team also confirmed that the enzyme's ability to cut anchors was essential for this effect, as a version of the enzyme that could not cut failed to change Tau levels.
Despite these promising shifts in the chemical balance of the brain, the study found that the delay caused by removing GDE2 was not enough to stop the disease in its tracks. By the time the mice reached nine months of age, the levels of harmful Tau phosphorylation had caught up to those in the normal mice, and the formation of tangles and the loss of neurons were indistinguishable between the two groups. This suggests that while GDE2 helps control the onset of Tau problems, it does not determine the final outcome of the disease in this model. The findings highlight that the mechanisms driving Tau pathology are complex and vary by brain region, and that simply slowing down the initial chemical changes may not be sufficient to prevent the eventual collapse of the brain's transport system. The work points to GDE2 as a new component in the intricate network that manages Tau, offering a clearer view of how upstream signals can influence the protein's behavior in the absence of other disease factors.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.